Open-angle Glaucoma (OAG)NCT07408154
Direct vs Standard SLT for Glaucoma: A Noninferiority Trial
A study testing Direct Selective laser Trabeculoplasty in people with Open-angle Glaucoma (OAG) and Ocular Hypertension (OHT), run by Medical University of South Carolina at 1 site in United States.
Trial summary
This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss. DSLT is a newer, non-contact technique that may improve comfort and efficiency. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Open-angle Glaucoma (OAG), Ocular Hypertension (OHT)
- What is being tested?
- Direct Selective laser Trabeculoplasty
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 172 participants
- Where
- 1 siteUnited States
- Study dates
- 27 Apr 2026to Oct 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Age ≥18 years
- Diagnosis of OAG (including exfoliative or pigmentary) or OHT
- Gonioscopically open angle (visible scleral spur 360°)
- Ability to consent and comply with follow-up
Who cannot join
- Angle-closure or secondary glaucomas
- IOP >35 mmHg despite therapy
- Corneal pathology interfering with laser or IOP measurement
- Recent ocular surgery (<6 months)
- Contraindications to study medications or procedures
- Cognitive impairment preventing consent
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
MUSC
Charleston, South Carolina, 29407
Jella An, MD, MBA, 843-792-1443, anjel@musc.edu
Jella An, MD, MBA
About this study
Official title: A Randomized Controlled Trial Comparing Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT) in Reducing Intraocular Pressure in Open-Angle Glaucoma
This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss. DSLT is a newer, non-contact technique that may improve comfort and efficiency. Participants will be randomly assigned to receive either DSLT or SLT and followed for 12 months to assess eye pressure, safety, and treatment outcomes.
- Being tested
- Direct Selective laser Trabeculoplasty
- Keywords
- Glaucoma, Open-Angle Glaucoma, Ocular Hypertension, Laser Trabeculoplasty, Intraocular Pressure
- Medical subject headings
- Glaucoma, Open-Angle, Ocular Hypertension, Glaucoma
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Direct Selective laser TrabeculoplastyDevice
The Direct Selective Laser Trabeculoplasty is a non-contact laser designed to manage IOP in patients with glaucoma. The traditional SLT required a gonioscopy lens to be placed over the patient's eyes to direct the laser towards the trabecular meshwork.
| Study group | Role | What they receive |
|---|---|---|
| Direct Selective Laser Trabeculoplasty | Experimental | This arm is going to receive the Direct SLT treatment Receives: Device: Direct Selective laser Trabeculoplasty |
| Traditional Selective Laser Trabeculoplasty | Active comparator | This arm is going to receive the Traditional SLT treatment which will act as a control for the experimental arm. Note that both lasers are Standard of Care (SOC) and FDA approved Receives: Device: Direct Selective laser Trabeculoplasty |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Intraocular Pressure at 12 months from baseline
Measured: 12 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted13 Feb 2026
- Study start27 Apr 2026
- Primary completionOct 2027 (estimated)
- Study completionOct 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Open-angle Glaucoma (OAG)Studies of the same condition, open and under way.
- More trials run by Medical University of South CarolinaThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 172 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Medical University of South Carolina
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Jella An, Medical University of South Carolina
- Investigators
- Jella An, MD, Principal investigator, Medical University of South Carolina
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07408154
- Sponsor's protocol ID
- Pro00148724
- Status last verified
- May 2026
- First submitted
- 6 Feb 2026
- Last updated
- 6 May 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- Yes
- Individual data sharing
- No: This is a MUSC only clinical trial and the data from enrolled patients will not be shared.
Study at a glance
From the registry record, last updated by the sponsor on 6 May 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Randomized Controlled Trial Comparing Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT) in Reducing Intraocular Pressure in Open-Angle Glaucoma
- ClinicalTrials.gov ID
- NCT07408154
- Acronym / sponsor ID
- Pro00148724
- Keywords
- Glaucoma, Open-Angle Glaucoma, Ocular Hypertension, Laser Trabeculoplasty, Intraocular Pressure
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 172 participants (estimated)
- Lead sponsor
- Medical University of South CarolinaUniversity, hospital or other
- Study start
- 27 Apr 2026 (actual)
- Primary completion
- Oct 2027 (estimated)
- Study completion
- Oct 2027 (estimated)
- First posted
- 13 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This study compares two FDA-approved laser treatments for glaucoma: Direct Selective Laser Trabeculoplasty (DSLT) and Selective Laser Trabeculoplasty (SLT). Both procedures aim to lower eye pressure and prevent vision loss. DSLT is a newer, non-contact technique that may improve comfort and efficiency. Participants will be randomly assigned to receive either DSLT or SLT and followed for 12 months to assess eye pressure, safety, and treatment outcomes.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Direct Selective Laser Trabeculoplasty | Experimental | Device: Direct Selective laser TrabeculoplastyThis arm is going to receive the Direct SLT treatment |
| Traditional Selective Laser Trabeculoplasty | Active comparator | Device: Direct Selective laser TrabeculoplastyThis arm is going to receive the Traditional SLT treatment which will act as a control for the experimental arm. Note that both lasers are Standard of Care (SOC) and FDA approved |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (4 listed)
- Age ≥18 years
- Diagnosis of OAG (including exfoliative or pigmentary) or OHT
- Gonioscopically open angle (visible scleral spur 360°)
- Ability to consent and comply with follow-up
Key exclusion criteria (6 listed)
- Angle-closure or secondary glaucomas
- IOP >35 mmHg despite therapy
- Corneal pathology interfering with laser or IOP measurement
- Recent ocular surgery (<6 months)
- Contraindications to study medications or procedures
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Direct Selective laser TrabeculoplastyThe Direct Selective Laser Trabeculoplasty is a non-contact laser designed to manage IOP in patients with glaucoma. The traditional SLT required a gonioscopy lens to be placed over the patient's eyes to direct the laser towards the trabecular meshwork. | Device | Direct Selective Laser Trabeculoplasty, Traditional Selective Laser Trabeculoplasty |
Primary outcome
Change in Intraocular Pressure at 12 months from baseline
Time frame: 12 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 6 May 2026.
- Individual participant dataSharing planned: No. This is a MUSC only clinical trial and the data from enrolled patients will not be shared.
Related trials for Open-angle Glaucoma (OAG)
RecruitingPhase 4
Adaptive Optics OCT Evaluation of Rhopressa's Effects on the Retinal Ganglion Cells in Glaucoma Patients
Open Angle Glaucoma (OAG), Glaucoma
Recruiting
Safety and Effectiveness of the VisiPlate Aqueous Shunt in Patients With Refractory Open-Angle Glaucoma
Open Angle Glaucoma (OAG)
RecruitingObservational study
iDose TR Administration in an Office-Based Surgery Setting
Open Angle Glaucoma (OAG), Ocular Hypertension (OHT)
RecruitingPhase 1/2
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
RecruitingObservational study
A Study to Assess Brillouin Hydration Mapping for the Evaluation of Ocular Tissues and Diseases
Fuchs Endothelial Corneal Dysfunction, Open Angle Glaucoma (OAG)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jella An, MD principal investigator
Medical University of South Carolina
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Direct Selective laser Trabeculoplasty in people with Open-angle Glaucoma (OAG) and Ocular Hypertension (OHT), run by Medical University of South Carolina at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 6 May 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Intraocular Pressure at 12 months from baseline (time frame: 12 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 6 May 2026.